BioForce Nanosciences (OTCMKTS:BFNH) & Lantern Pharma (NASDAQ:LTRN) Head-To-Head Analysis

BioForce Nanosciences (OTCMKTS:BFNH) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Valuation & Earnings

This table compares BioForce Nanosciences and Lantern Pharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioForce Nanosciences	N/A	N/A	-$490,000.00	($0.04)	-16.25
Lantern Pharma	N/A	N/A	-$20.78 million	($1.78)	-2.31

BioForce Nanosciences is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

28.6% of Lantern Pharma shares are owned by institutional investors. 39.5% of BioForce Nanosciences shares are owned by company insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

BioForce Nanosciences has a beta of -0.76, indicating that its stock price is 176% less volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

Profitability

This table compares BioForce Nanosciences and Lantern Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioForce Nanosciences	N/A	N/A	-30,300.56%
Lantern Pharma	N/A	-99.89%	-81.58%

Analyst Ratings

This is a breakdown of current ratings and target prices for BioForce Nanosciences and Lantern Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioForce Nanosciences	0	0	0	0	0.00
Lantern Pharma	1	0	1	0	2.00

Lantern Pharma has a consensus price target of $25.00, indicating a potential upside of 508.27%. Given Lantern Pharma’s stronger consensus rating and higher possible upside, analysts plainly believe Lantern Pharma is more favorable than BioForce Nanosciences.

Summary

Lantern Pharma beats BioForce Nanosciences on 7 of the 11 factors compared between the two stocks.

About BioForce Nanosciences

BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. The company offers private label products with distributors and manufacturing providers. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, mass merchandisers, and online at www.bioforceeclipse.com, as well as through social media and telemarketing channels. BioForce Nanosciences Holdings, Inc. is based in Virginia Beach, Virginia.

About Lantern Pharma

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.